nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—Peptide GPCRs—LHCGR—polycystic ovary syndrome	0.0285	0.0496	CbGpPWpGaD
Fosaprepitant—Body temperature decreased—Metformin—polycystic ovary syndrome	0.0274	0.0644	CcSEcCtD
Fosaprepitant—Hypothermia—Metformin—polycystic ovary syndrome	0.0274	0.0644	CcSEcCtD
Fosaprepitant—Upset stomach—Metformin—polycystic ovary syndrome	0.0234	0.0551	CcSEcCtD
Fosaprepitant—TACR1—Peptide GPCRs—FSHR—polycystic ovary syndrome	0.0209	0.0363	CbGpPWpGaD
Fosaprepitant—Chest discomfort—Metformin—polycystic ovary syndrome	0.0174	0.0408	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—NPB—polycystic ovary syndrome	0.0161	0.0279	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—PTAFR—polycystic ovary syndrome	0.0127	0.0221	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—ADRA1D—polycystic ovary syndrome	0.0123	0.0215	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—ADRA1B—polycystic ovary syndrome	0.012	0.0209	CbGpPWpGaD
Fosaprepitant—Lethargy—Metformin—polycystic ovary syndrome	0.0114	0.0267	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PTAFR—polycystic ovary syndrome	0.0114	0.0198	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1D—polycystic ovary syndrome	0.011	0.0192	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—NPB—polycystic ovary syndrome	0.0108	0.0187	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1B—polycystic ovary syndrome	0.0107	0.0187	CbGpPWpGaD
Fosaprepitant—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.0102	0.0239	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—RUNX3—polycystic ovary syndrome	0.00976	0.017	CbGpPWpGaD
Fosaprepitant—Abdominal distension—Metformin—polycystic ovary syndrome	0.0097	0.0228	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00923	0.0217	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—ADRA1A—polycystic ovary syndrome	0.00908	0.0158	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—PTGER3—polycystic ovary syndrome	0.00899	0.0156	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—LHCGR—polycystic ovary syndrome	0.00899	0.0156	CbGpPWpGaD
Fosaprepitant—Infestation—Metformin—polycystic ovary syndrome	0.00859	0.0202	CcSEcCtD
Fosaprepitant—Infestation NOS—Metformin—polycystic ovary syndrome	0.00859	0.0202	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—GNRH1—polycystic ovary syndrome	0.00845	0.0147	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—PTAFR—polycystic ovary syndrome	0.00841	0.0146	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—NPB—polycystic ovary syndrome	0.0082	0.0143	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRA1D—polycystic ovary syndrome	0.00816	0.0142	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1A—polycystic ovary syndrome	0.00812	0.0141	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRA1B—polycystic ovary syndrome	0.00794	0.0138	CbGpPWpGaD
Fosaprepitant—Bradycardia—Metformin—polycystic ovary syndrome	0.00785	0.0184	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00767	0.018	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00758	0.0178	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—polycystic ovary syndrome	0.00755	0.0131	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—NGFR—polycystic ovary syndrome	0.00726	0.0126	CbGpPWpGaD
Fosaprepitant—Eye disorder—Metformin—polycystic ovary syndrome	0.00721	0.0169	CcSEcCtD
Fosaprepitant—Flushing—Metformin—polycystic ovary syndrome	0.00716	0.0168	CcSEcCtD
Fosaprepitant—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00716	0.0168	CcSEcCtD
Fosaprepitant—Angiopathy—Metformin—polycystic ovary syndrome	0.007	0.0164	CcSEcCtD
Fosaprepitant—Immune system disorder—Metformin—polycystic ovary syndrome	0.00696	0.0164	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00695	0.0163	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.00684	0.0119	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—PTGER3—polycystic ovary syndrome	0.00684	0.0119	CbGpPWpGaD
Fosaprepitant—Erythema—Metformin—polycystic ovary syndrome	0.00671	0.0158	CcSEcCtD
Fosaprepitant—Malnutrition—Metformin—polycystic ovary syndrome	0.00671	0.0158	CcSEcCtD
Fosaprepitant—Flatulence—Metformin—polycystic ovary syndrome	0.00661	0.0155	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00658	0.0115	CbGpPWpGaD
Fosaprepitant—Dysgeusia—Metformin—polycystic ovary syndrome	0.00657	0.0154	CcSEcCtD
Fosaprepitant—Muscle spasms—Metformin—polycystic ovary syndrome	0.00645	0.0152	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.0064	0.0111	CbGpPWpGaD
Fosaprepitant—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00623	0.0146	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.00621	0.0108	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TH—polycystic ovary syndrome	0.0062	0.0108	CbGpPWpGaD
Fosaprepitant—Malaise—Metformin—polycystic ovary syndrome	0.00605	0.0142	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.00605	0.0105	CbGpPWpGaD
Fosaprepitant—Syncope—Metformin—polycystic ovary syndrome	0.00602	0.0141	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.00602	0.0105	CbGpPWpGaD
Fosaprepitant—Palpitations—Metformin—polycystic ovary syndrome	0.00593	0.0139	CcSEcCtD
Fosaprepitant—Loss of consciousness—Metformin—polycystic ovary syndrome	0.0059	0.0139	CcSEcCtD
Fosaprepitant—Hypertension—Metformin—polycystic ovary syndrome	0.00579	0.0136	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00579	0.0101	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.00572	0.00996	CbGpPWpGaD
Fosaprepitant—Chest pain—Metformin—polycystic ovary syndrome	0.00571	0.0134	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—GHRL—polycystic ovary syndrome	0.0057	0.00993	CbGpPWpGaD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00567	0.0133	CcSEcCtD
Fosaprepitant—Discomfort—Metformin—polycystic ovary syndrome	0.00565	0.0133	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—GHRL—polycystic ovary syndrome	0.00563	0.00981	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.00559	0.00974	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—AR—polycystic ovary syndrome	0.00552	0.0096	CbGpPWpGaD
Fosaprepitant—Oedema—Metformin—polycystic ovary syndrome	0.00548	0.0129	CcSEcCtD
Fosaprepitant—Infection—Metformin—polycystic ovary syndrome	0.00544	0.0128	CcSEcCtD
Fosaprepitant—Shock—Metformin—polycystic ovary syndrome	0.00539	0.0127	CcSEcCtD
Fosaprepitant—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00537	0.0126	CcSEcCtD
Fosaprepitant—Skin disorder—Metformin—polycystic ovary syndrome	0.00532	0.0125	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.0053	0.0124	CcSEcCtD
Fosaprepitant—Hypotension—Metformin—polycystic ovary syndrome	0.00512	0.012	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.00512	0.00891	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—polycystic ovary syndrome	0.0051	0.00888	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.00501	0.00872	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—LEP—polycystic ovary syndrome	0.00496	0.00863	CbGpPWpGaD
Fosaprepitant—Dyspnoea—Metformin—polycystic ovary syndrome	0.00488	0.0115	CcSEcCtD
Fosaprepitant—Somnolence—Metformin—polycystic ovary syndrome	0.00487	0.0114	CcSEcCtD
Fosaprepitant—Dyspepsia—Metformin—polycystic ovary syndrome	0.00482	0.0113	CcSEcCtD
Fosaprepitant—Decreased appetite—Metformin—polycystic ovary syndrome	0.00476	0.0112	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00473	0.0111	CcSEcCtD
Fosaprepitant—Fatigue—Metformin—polycystic ovary syndrome	0.00472	0.0111	CcSEcCtD
Fosaprepitant—Constipation—Metformin—polycystic ovary syndrome	0.00468	0.011	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00463	0.00807	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.00458	0.00798	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Metformin—polycystic ovary syndrome	0.00451	0.0106	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00448	0.0105	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—NR3C1—polycystic ovary syndrome	0.00446	0.00777	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.00441	0.00768	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00436	0.00759	CbGpPWpGaD
Fosaprepitant—Urticaria—Metformin—polycystic ovary syndrome	0.00435	0.0102	CcSEcCtD
Fosaprepitant—Abdominal pain—Metformin—polycystic ovary syndrome	0.00433	0.0102	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00426	0.00741	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00421	0.00733	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00419	0.0073	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.0041	0.00714	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.0041	0.00714	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—SCT—polycystic ovary syndrome	0.00408	0.00711	CbGpPWpGaD
Fosaprepitant—Asthenia—Metformin—polycystic ovary syndrome	0.00393	0.00923	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.0039	0.00678	CbGpPWpGaD
Fosaprepitant—Pruritus—Metformin—polycystic ovary syndrome	0.00388	0.00911	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00387	0.00673	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00387	0.00673	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00381	0.00663	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.00378	0.00658	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Metformin—polycystic ovary syndrome	0.00375	0.00881	CcSEcCtD
Fosaprepitant—Dizziness—Metformin—polycystic ovary syndrome	0.00362	0.00851	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00362	0.0063	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00351	0.00611	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00351	0.00611	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00351	0.00611	CbGpPWpGaD
Fosaprepitant—Vomiting—Metformin—polycystic ovary syndrome	0.00348	0.00818	CcSEcCtD
Fosaprepitant—Rash—Metformin—polycystic ovary syndrome	0.00345	0.00812	CcSEcCtD
Fosaprepitant—Dermatitis—Metformin—polycystic ovary syndrome	0.00345	0.00811	CcSEcCtD
Fosaprepitant—Headache—Metformin—polycystic ovary syndrome	0.00343	0.00806	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00342	0.00595	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00329	0.00572	CbGpPWpGaD
Fosaprepitant—Nausea—Metformin—polycystic ovary syndrome	0.00325	0.00765	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00319	0.00555	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00313	0.00544	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00311	0.00541	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.0031	0.0054	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—POMC—polycystic ovary syndrome	0.00291	0.00507	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.00288	0.00501	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00284	0.00495	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00283	0.00493	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00282	0.00491	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00259	0.00451	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00257	0.00448	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.00249	0.00434	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NPB—polycystic ovary syndrome	0.00249	0.00433	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00246	0.00429	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00241	0.00419	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00238	0.00415	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.00235	0.00409	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.00231	0.00402	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00226	0.00394	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00225	0.00391	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00224	0.00389	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.00221	0.00384	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.0022	0.00383	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.00219	0.00381	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	0.00214	0.00373	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—SCT—polycystic ovary syndrome	0.0021	0.00365	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.00207	0.00361	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.00207	0.00361	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.002	0.00348	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.00195	0.0034	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.00194	0.00338	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00188	0.00328	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IL6—polycystic ovary syndrome	0.00185	0.00322	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00183	0.00319	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.00179	0.00311	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00167	0.0029	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.00163	0.00283	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.00152	0.00264	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.00149	0.00259	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	0.00148	0.00258	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.00148	0.00257	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.00143	0.00249	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.00139	0.00242	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FST—polycystic ovary syndrome	0.00135	0.00236	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.00135	0.00234	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.00134	0.00233	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LHB—polycystic ovary syndrome	0.00132	0.0023	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.00129	0.00225	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.00125	0.00218	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.00125	0.00217	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SCT—polycystic ovary syndrome	0.00124	0.00216	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.00122	0.00213	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.00118	0.00206	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.00116	0.00202	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.00115	0.002	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.00115	0.00199	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.00113	0.00197	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.00107	0.00187	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.00106	0.00184	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—INSR—polycystic ovary syndrome	0.00101	0.00176	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000963	0.00168	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000948	0.00165	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000938	0.00163	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000872	0.00152	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000872	0.00152	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.00084	0.00146	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000832	0.00145	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000811	0.00141	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000808	0.00141	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000768	0.00134	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000763	0.00133	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRL—polycystic ovary syndrome	0.000761	0.00132	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000733	0.00128	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000722	0.00126	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000669	0.00117	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000638	0.00111	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000626	0.00109	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000536	0.000933	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LEP—polycystic ovary syndrome	0.000525	0.000913	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000468	0.000815	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—POMC—polycystic ovary syndrome	0.000451	0.000785	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—INS—polycystic ovary syndrome	0.000448	0.00078	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000434	0.000755	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000433	0.000754	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000412	0.000717	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000332	0.000577	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000283	0.000493	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL6—polycystic ovary syndrome	0.000196	0.000341	CbGpPWpGaD
